Drug intelligence / Profile preview

PCP-PBMCs

Development stage: Phase 3
Lead developer: DuoGenic StemCells Corporation
Modality: Cell Therapies
Administration: Intraarticular

Overview

PCP-PBMCs is an autologous cell therapy consisting of purified peripheral blood mononuclear cells (PBMCs) developed by DuoGenic StemCells Corporation (DGSC). The product is obtained through a proprietary peripheral-blood cell purification (PCP) process. It is designed for intra-articular injection to treat knee osteoarthritis (KOA). The therapy aims to leverage the anti-inflammatory and regenerative potential of mononuclear cells (including lymphocytes and monocytes) to reduce pain, restore motor function, and improve the quality of life in patients with degenerative joint disease. It is currently being evaluated in Phase II/III clinical trials as an alternative to corticosteroids like methylprednisolone.

Other names: autologous peripheral blood mononuclear cellsPCP-PBMCs injection

Beyond the preview

Go deeper on PCP-PBMCs.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PCP-PBMCs.

Explore the full profile